Back to search results

Study of ZEN003694 and Talazoparib for Recurrent Ovarian Cancer

This study is testing a combination of two drugs, ZEN003694 and Talazoparib, for women with recurrent ovarian, fallopian tube, or primary peritoneal carcinoma (cancers that start in the lining of the abdomen). ZEN003694 works by slowing down cancer cell growth, and Talazoparib kills cancer cells by targeting an enzyme called PARP. You may be able to join if you are a woman aged 18 or older, have one of these cancers, and have previously received PARP inhibitor (PARPi) therapy. The study aims to see how well this drug combination shrinks tumors, with responses measured for up to 48 months. The current status of this study is unclear, and it plans to enroll 33 participants.

Study design
This is a Phase 2, open-label study, meaning both you and your doctors will know which treatments you are receiving. It will enroll approximately 33 participants.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
The study will measure your response to treatment for up to 48 months.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT05071937

ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer

Recruiting
PHASE2Ages 18+InterventionalTreatment
Alexander B Olawaiye, MD
~33 participants
Updated 2026-06-18 on ClinicalTrials.gov
What's tested:ZEN003694Talazoparib

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Objective Response
Measured over Up to 48 months

Conditions

Ovarian Cancer
Peritoneal Cancer
Fallopian Tube Cancer

Explore related trials

Fallopian Tube CarcinomaMalignant Ovarian NeoplasmMalignant Peritoneal Neoplasm

Where it's being run

1 sites across 1 states
Pennsylvania1

Study leadership

  • Alexander B Olawaiye, MD · PRINCIPAL_INVESTIGATOR · UPMC Hillman Cancer Center

Who to contact

Kelsey Mitch, BSN
[email protected]
412-648-6417
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Exclusion

HIV-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months of enrollment are eligible for this trial.
Patients with a known history of Hepatitis B (defined as Hepatitis B surface antigen \[HBsAg\] reactive) or known active Hepatitis C virus (defined as HCV RNA \[qualitative\] is detected) infection are allowed to be included if: participant on a stable dose of antiviral therapy, HBV viral load below the limit of quantification. HCV viral load below the limit of quantification. 35. Major surgery other than diagnostic surgery, dental surgery or stenting within 4 weeks prior to the first administration of study drug 36. Concurrent participation in another clinical investigational treatment trial 37. Any other reason that in the opinion of the Investigator would prevent the patient from completing participation or following the study schedule

What this trial measures

  • Objective ResponseUp to 48 months

    Confirmed complete response or partial response by RECIST 1.1. Per RECIST v1.1. Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. Partial Response (PR): At least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters.